Last updated: 2026-09-16 12:18:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
HCW Biologics Inc. (HCWB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2,06, with a market capitalisation of $4,04M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,50 to $29,34. This page covers its latest market performance, valuation, price trends and company information.
$4,04M | |
$2,12 | |
$1.866,00 | |
$1,50 | |
$2,05 | |
36,00 | |
180,85K | |
-- | |
$29,34 | |
$1,50 | |
-- | |
-- |
HCW Biologics Inc. (HCWB) is trading at $2,06 in pre-market trading as of 2026-09-16 11:07:00, up 0,54% ($0,01) from the previous close of $2,05
Pre-market trading shows how investors are pricing HCWB before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, HCW Biologics Inc. (HCWB) moved from $2,94 to $2,06, representing a decline of 29,90% ($0,88).
The stock traded between $2,04 and $2,97 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 501,42 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2,0%
HCWB is currently trading at $2,06, placing it 2,0% of the way from its 52-week low of $1,50 to its 52-week high of $29,34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 35 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of HCW Biologics Inc. (HCWB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.